Antonio Espinosa de los Monteros-Zúñiga , Jorge Luis Almazán , Guadalupe Martínez-Lorenzana , Mónica C. Guillen-Paredes , G. Aleph Prieto , Miguel Condés-Lara , Abimael González-Hernández
{"title":"偏置的OTR配体-阿托西班和卡霉素-不同程度地抑制早期或晚期福尔马林诱导的大鼠伤害感受","authors":"Antonio Espinosa de los Monteros-Zúñiga , Jorge Luis Almazán , Guadalupe Martínez-Lorenzana , Mónica C. Guillen-Paredes , G. Aleph Prieto , Miguel Condés-Lara , Abimael González-Hernández","doi":"10.1016/j.neuropharm.2025.110487","DOIUrl":null,"url":null,"abstract":"<div><div>Males are more sensitive to intrathecal oxytocin-induced antinociception than females. This antinociception has been linked to oxytocin receptor (OTR) activation. Canonically, OTR is coupled to Gq but can also activate Gi/o proteins. In males, the formalin test showed that oxytocin prevented early nociception (flinches) via the Gq pathway, whereas long-lasting hypersensitivity was halted by Gi/o activation. Here, we tested the effects of biased OTR ligands carbetocin (Gq) and atosiban (Gi/o) on formalin-induced nociception in male and female Wistar rats. Specifically, we assessed the effects of intrathecal carbetocin and atosiban on early (flinches) and late (paw withdrawal threshold) formalin-induced nociception. Pretreatment with L-368,899 (OTR antagonist), U-73122 (phospholipase C inhibitor), L-NAME (nitric oxide synthase inhibitor), or <em>pertussis</em> toxin (a Gi/o inhibitor) was used to dissect the pathways involved. Furthermore, late activation of Akt, ERK1/2, and S6 ribosomal (S6) protein was tracked in spinal tissue by immunoblotting. Carbetocin prevented early nociception in males, whereas atosiban precluded late nociception in both sexes. The antinociception induced by carbetocin and atosiban was abolished by L-368,899, pointing out the role of OTR. Pretreatment with U-73122 or L-NAME blocked the carbetocin effect, whereas <em>pertussis</em> toxin prevented the atosiban effect. Late hypersensitivity correlated with increased levels of phosphorylated S6 protein in the spinal tissue, an effect partly blocked by atosiban. These data suggest that carbetocin prevents early nociception in males via OTR-Gq, and atosiban blocks late hypersensitivity in both sexes via OTR-Gi/o, implying that OTR-biased activation underlies the sexual dimorphism observed in oxytocin-induced antinociception.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"275 ","pages":"Article 110487"},"PeriodicalIF":4.6000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The biased OTR ligands -atosiban and carbetocin- differentially inhibit early or late formalin-induced nociception in rats\",\"authors\":\"Antonio Espinosa de los Monteros-Zúñiga , Jorge Luis Almazán , Guadalupe Martínez-Lorenzana , Mónica C. Guillen-Paredes , G. Aleph Prieto , Miguel Condés-Lara , Abimael González-Hernández\",\"doi\":\"10.1016/j.neuropharm.2025.110487\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Males are more sensitive to intrathecal oxytocin-induced antinociception than females. This antinociception has been linked to oxytocin receptor (OTR) activation. Canonically, OTR is coupled to Gq but can also activate Gi/o proteins. In males, the formalin test showed that oxytocin prevented early nociception (flinches) via the Gq pathway, whereas long-lasting hypersensitivity was halted by Gi/o activation. Here, we tested the effects of biased OTR ligands carbetocin (Gq) and atosiban (Gi/o) on formalin-induced nociception in male and female Wistar rats. Specifically, we assessed the effects of intrathecal carbetocin and atosiban on early (flinches) and late (paw withdrawal threshold) formalin-induced nociception. Pretreatment with L-368,899 (OTR antagonist), U-73122 (phospholipase C inhibitor), L-NAME (nitric oxide synthase inhibitor), or <em>pertussis</em> toxin (a Gi/o inhibitor) was used to dissect the pathways involved. Furthermore, late activation of Akt, ERK1/2, and S6 ribosomal (S6) protein was tracked in spinal tissue by immunoblotting. Carbetocin prevented early nociception in males, whereas atosiban precluded late nociception in both sexes. The antinociception induced by carbetocin and atosiban was abolished by L-368,899, pointing out the role of OTR. Pretreatment with U-73122 or L-NAME blocked the carbetocin effect, whereas <em>pertussis</em> toxin prevented the atosiban effect. Late hypersensitivity correlated with increased levels of phosphorylated S6 protein in the spinal tissue, an effect partly blocked by atosiban. These data suggest that carbetocin prevents early nociception in males via OTR-Gq, and atosiban blocks late hypersensitivity in both sexes via OTR-Gi/o, implying that OTR-biased activation underlies the sexual dimorphism observed in oxytocin-induced antinociception.</div></div>\",\"PeriodicalId\":19139,\"journal\":{\"name\":\"Neuropharmacology\",\"volume\":\"275 \",\"pages\":\"Article 110487\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuropharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0028390825001935\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390825001935","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
The biased OTR ligands -atosiban and carbetocin- differentially inhibit early or late formalin-induced nociception in rats
Males are more sensitive to intrathecal oxytocin-induced antinociception than females. This antinociception has been linked to oxytocin receptor (OTR) activation. Canonically, OTR is coupled to Gq but can also activate Gi/o proteins. In males, the formalin test showed that oxytocin prevented early nociception (flinches) via the Gq pathway, whereas long-lasting hypersensitivity was halted by Gi/o activation. Here, we tested the effects of biased OTR ligands carbetocin (Gq) and atosiban (Gi/o) on formalin-induced nociception in male and female Wistar rats. Specifically, we assessed the effects of intrathecal carbetocin and atosiban on early (flinches) and late (paw withdrawal threshold) formalin-induced nociception. Pretreatment with L-368,899 (OTR antagonist), U-73122 (phospholipase C inhibitor), L-NAME (nitric oxide synthase inhibitor), or pertussis toxin (a Gi/o inhibitor) was used to dissect the pathways involved. Furthermore, late activation of Akt, ERK1/2, and S6 ribosomal (S6) protein was tracked in spinal tissue by immunoblotting. Carbetocin prevented early nociception in males, whereas atosiban precluded late nociception in both sexes. The antinociception induced by carbetocin and atosiban was abolished by L-368,899, pointing out the role of OTR. Pretreatment with U-73122 or L-NAME blocked the carbetocin effect, whereas pertussis toxin prevented the atosiban effect. Late hypersensitivity correlated with increased levels of phosphorylated S6 protein in the spinal tissue, an effect partly blocked by atosiban. These data suggest that carbetocin prevents early nociception in males via OTR-Gq, and atosiban blocks late hypersensitivity in both sexes via OTR-Gi/o, implying that OTR-biased activation underlies the sexual dimorphism observed in oxytocin-induced antinociception.
期刊介绍:
Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).